Lupin, the second largest pharma major with net sales of Rs.17,120 crore, has received final approval for its Tydemy (drospirenone, ethinyl estradiol, and levomefolate calcium tablets, 3mg/0.03 mg/ 0.451 mg and levomemfolate calcium tablets 0.451 mg) from US FDA to market a generic version of Safyral tablets of Bayer HealthCare Pharmaceuticals Inc.
Lupin's Tydemy is the AB rated generic equivalent of Safyral tablets of Bayer HeallthCare. Tydemy is indicated for use by women to prevent pregnancy and to raise folate levels in women who choose to use an oral contraceptive for contraception. These tablets had annual sales of app. US$ 22.9 million in the US.
Lupin scrip of Rs.2 each closed higher by Rs.8.40 to Rs.852 today on BSE.